0001175680falseNONE00011756802026-11-122026-11-12

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2026

 

 

CytoDyn, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-49908

83-1887078

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1111 MAIN STREET, SUITE 660

 

VANCOUVER, Washington

 

98660

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 360 980-8524

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

None

 

N/A

 

N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c) and (e) On November 17, 2026, the Company entered into an agreement with Lauren Wilcoxen, Ph.D. (“Dr. Wilcoxen”), under which Dr. Wilcoxen will serve as the Company’s Chief Operating Officer (“COO”) and Head of Regulatory Affairs, effective November 20, 2026 (the “Employment Agreement”). The Company’s Board of Directors (the “Board”) approved the election of Dr. Wilcoxen as the Company’s COO on November 12, 2026.

 

Dr. Wilcoxen, age 40, brings extensive experience in regulatory affairs, clinical development and biotechnology operations, including a track record of advancing oncology programs through key regulatory milestones. Over the past several years, Dr. Wilcoxen has provided regulatory consulting and operational support services to a variety of public and private biotechnology and pharmaceutical companies. Most recently, from August 2026 to November 2026, she served as Senior Vice President, Regulatory Affairs of Xilio Therapeutics, Inc. (NASDAQ: XLO), a publicly traded clinical-stage biotechnology company. From June 2025 to August 2026, Dr. Wilcoxen provided independent regulatory consulting services to oncology biotechnology companies through Clarivance Bio, LLC. From May 2022 to October 2025, she served as Senior Vice President, Product Development and Regulatory Affairs of Checkpoint Therapeutics, Inc. (formerly NASDAQ: CKPT), which was a publicly traded clinical-stage biotechnology company until its acquisition by Sun Pharmaceutical Industries, Inc. From June 2020 to September 2022, she served as Vice President, Regulatory Affairs of Istari Oncology, Inc., a private clinical-stage biotechnology company.

 

There are no family relationships, as defined in Item 401 of Regulation S-K, between Dr. Wilcoxen and any of the Company’s other executive officers and directors. Other than the Employment Agreement, there is no arrangement or understanding between Dr. Wilcoxen and any other person pursuant to which she was appointed as COO of the Company. There are no transactions in which Dr. Wilcoxen has an interest requiring disclosure under Item 404(a) of Regulation S-K.

 

Dr. Wilcoxen’s initial compensation under the Employment Agreement, which was approved by the Board’s Compensation Committee (the “Committee”), includes the following: an initial annual base salary of $425,000, subject to periodic adjustment, eligibility to participate in the Company’s short- and long-term incentive plans in which other executive officers may participate, including a target annual bonus of 40% of her base salary earned for services during the fiscal year ending May 31, 2027; and an award of a nonqualified stock option to purchase 4,500,000 shares of the Company’s common stock under the Company’s Amended and Restated 2012 Equity Incentive Plan. The stock options will have an exercise price equal to the closing price of the common stock on the grant date and will vest over a four-year period beginning on the grant date. Under the Employment Agreement, either party may terminate Dr. Wilcoxen’s employment with the Company at any time, with or without cause, and with or without advance notice. The Employment Agreement also provides for certain severance benefits. The foregoing description of the Employment Agreement is not complete and is qualified in its entirety by reference to the complete text of the Employment Agreement, a copy of which is filed herewith as Exhibit 10.1.

Item 7.01 Regulation FD Disclosure.

A copy of the press release issued by the Company on November 17, 2026, announcing Dr. Wilcoxen’s appointment as the Company’s COO is furnished as Exhibit 99.1.

Item 9.01 Financial Statement and Exhibits.

(d) Exhibits.

 

 

 

 

 

 

Exhibit No.

Description

10.1

 

 

Employment Agreement between the Company and Lauren Wilcoxen, dated November 17, 2026

99.1

 

Press Release dated November 17, 2026**

104

 

Cover Page Interactive Data File (formatted as inline XBRL)

** Furnished, not filed.

 


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

CYTODYN INC.

 

 

 

 

Date:

November 17, 2026

By:

/s/ Tyler Blok

 

 

 

Tyler Blok
Chief Legal Officer